# A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

> **NCT07709494** · PHASE1 · RECRUITING · sponsor: **Revagenix, Inc.** · enrollment: 64 (estimated)

## Conditions studied

- Healthy Participants
- Non-cystic Fibrosis Bronchiectasis

## Interventions

- **COMBINATION_PRODUCT:** Rev-56 for Inhalation
- **DRUG:** Placebo: Normal saline

## Key facts

- **NCT ID:** NCT07709494
- **Lead sponsor:** Revagenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709494, "A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*